Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 5/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.47 |
| ▸ | ABL1 | P00519 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13310660 | 0.85 | RPS6KA3 (0.43) | LMNADGAT1RPS6KA3NISCH | |
| SCHEMBL28109293 | 0.81 | CYP11B1 (0.50) | CYP11B1CYP11B2ABL1PTGS2DHODH | |
| SCHEMBL10272837 | 0.81 | ABL1 (0.55) | CYP11B1CYP11B2ABL1LMNAPTGS2 | |
| SCHEMBL17795041 | 0.80 | CYP11B1 (0.53) | CYP11B1CYP11B2ABL1PTGS2DHODH | |
| SCHEMBL14900842 | 0.80 | CYP11B1 (0.51) | CYP11B1CYP11B2ABL1LMNAPTGS2 | |
| SCHEMBL20437899 | 0.79 | LMNA (0.58) | CYP11B1CYP11B2ABL1LMNAPTGS2 | |
| SCHEMBL19374726 | 0.77 | LMNA (0.39) | CYP11B1CYP11B2ABL1LMNACYP17A1 | |
| SCHEMBL21180023 | 0.77 | ERN1 (0.44) | CYP11B1CYP11B2ABL1LMNAPTGS2 | |
| SCHEMBL20437906 | 0.77 | CYP11B1 (0.51) | CYP11B1CYP11B2ABL1PTGS2GRIA2 | |
| SCHEMBL20437891 | 0.77 | ABL1 (0.46) | CYP11B1CYP11B2ABL1GRIA2DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703757-B2 | Compounds and methods for CDK8 modulation and indications therefor | PLEXXIKON INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20180215763-A1 | COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215763-A1 | COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703757-B2 | Compounds and methods for CDK8 modulation and indications therefor | CDK8, CDK7, CDK18 | CYP11B1 426/4885CYP11B2 517/4885ABL1 936/4885 |
| US-20180215763-A1 | COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR | CDK8, CDK7, CDK18 | CYP11B1 426/4885CYP11B2 517/4885ABL1 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.